A Recent HIV Diagnosis Is Associated with Non-Completion of Isoniazid Preventive Therapy in an HIV-Infected Cohort in Cape Town

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Oni, Tolu ^a,b,c   Tsekela, Relebohile ^a   Kwaza, Bekekile ^a   Manjezi, Lulama ^d   Bangani, Nonzwakazi ^a   Wilkinson, Katalin A ^a,e   Coetzee, David ^c   Wilkinson, Robert J ^a,b,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Khayelitsha Hospital   (South Africa)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ISONIAZID;

ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CARRIER; DISEASE TRANSMISSION; DRINKING BEHAVIOR; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SELF REPORT; SMOKING; SOUTH AFRICA; TREATMENT RESPONSE; TUBERCULIN TEST;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; PATIENT COMPLIANCE; SOUTH AFRICA; TIME FACTORS;

EID: 84871456874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052489     Document Type: Article

References (21)

1. Corbett E, Watt C, Walker N, Maher D, Williams B, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
2. Dye C, (2006) Global epidemiology of tuberculosis. Lancet 367: 938-940.
3. WHO (2011) Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva. p. 1-50.
4. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, et al. (2011) 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377: 1588-1598.
5. Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, et al. (2010) Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS 24Suppl 5: S45-8.
6. WHO (2011) Global Tuberculosis Control Report. World Health Organisation, Geneva p. 1-82.
7. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, et al. (2010) Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 24Suppl 5: S57-65.
8. Li J, Munsiff SS, Tarantino T, Dorsinville M, (2010) Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 14: e292-7.
9. Anibarro L, Casas S, Paz-Esquete J, Gonzalez L, Pena A, et al. (2010) Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis 14: 701-7.
10. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW, (2008) Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 12: 1235-54.
11. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W, (2010) Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 14: 1104-11.
12. Kwara A, Herold JS, Machan JT, Carter EJ, (2008) Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 133: 862-8.
13. Médecins Sans Frontierès (2012) Summary: Khayelitsha Activity Report 2001-2011. Available: http://www.msf.org.za/publication/summary-khayelitsha-activity-report-2001-2011. Accessed 2012 Jan 24.
14. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, et al. (2005) Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung Dis 9: 263-269.
15. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, et al. (2011) Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS ONE 6: e18435.
16. Thirumurthy H, Lester RT, (2012) M-health for health behaviour change in resource-limited settings: applications to HIV care and beyond. Bull World Health Org 90: 390.
17. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P, (1997) Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. AIDS 11: 107-112.
18. Lavigne M, Rocher I, Steensma C, Brassard P, (2006) The impact of smoking on adherence to treatment for latent tuberculosis infection. BMC Public Health 6: 66.
19. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, et al. (2011) New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365: 11-20.
20. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, et al. (2010) Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 14: 551-9.
21. Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, et al. (2009) Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis 13: 719-25.